Publications

June 2016
Case

Alnylam: Building a Biotechnology Powerhouse

By: Kevin Schulman

Alnylam is an early stage biomedical technology focused on commercial development of a novel technology platform, siRNA. This technology offered promise to treat rare genetic disorders that could not be treated with other technologies. Alnlyam's development entailed... View Details

Keywords: Technological Innovation; Commercialization; Health Disorders; Intellectual Property; Biotechnology Industry

March 1999
Case

Hans Fritz at Novartis Thailand (A): The First Month

By: Michael Y. Yoshino and Carin-Isabel Knoop

Dr. Hans Fritz is 37 years old when he arrives in Bangkok on March 1, 1998 to assume his position as general manager of Novartis Thailand. Novartis is the world's largest pharmaceutical company. He had lobbied to transition from a staff position to this line management... View Details

Keywords: Management Teams; Organizational Structure; Transition; Organizational Change and Adaptation; Working Conditions; Organizational Culture; Growth and Development Strategy; Crisis Management; Decision Making; Pharmaceutical Industry; Thailand

September 2003 (Revised March 2007)
Case

Direvo Biotech AG

Describes the financing and growth decisions facing Direvo, a young German biotech firm with a customer/partner that wants to become an investor. Also discusses the business model for Direvo's directed evolution technology, with applications in both industrial enzymes... View Details

Keywords: Business Model; Decisions; Business Exit or Shutdown; Value; Business Startups; Biotechnology Industry; Germany

11 Apr 2019
News

The DNA of Sustained Innovation

October 2023 (Revised April 2024)
Case

Accounting Red Flags or Red Herrings at Catalent? (A)

By: Joseph Pacelli, ZeSean Ali and Tom Quinn

Fund manager Janet Curie asked for a recommendation about the pharmaceutical company Catalent. The company seemed like a solid investment. However, a pair of research reports issued over the previous two months complicated this narrative. GlassHouse Research, a short... View Details

February 2000 (Revised October 2000)
Case

Kendle International Inc.

By: Dwight B. Crane, Paul W. Marshall and Indra Reinbergs

Candace Kendle and Christopher Bergen, the CEO and COO of Kendle International, Inc., are reviewing ways to finance the growth of their privately-owned company. Kendle is a contract research organization that conducts clinical drug trials for pharmaceutical and... View Details

Keywords: Acquisition; Financing and Loans; Venture Capital; Stock Options; Banks and Banking; Debt Securities; International Finance; Financial Strategy; Management Skills; Private Ownership; Initial Public Offering; Pharmaceutical Industry; Pharmaceutical Industry

Article

Prosocial Bonuses Increase Employee Satisfaction and Team Performance

By: Lalin Anik, Lara B. Aknin, Elizabeth W. Dunn, Michael I. Norton and Jordi Quoidbach

In three field studies, we explore the impact of providing employees and teammates with prosocial bonuses, a novel type of bonus spent on others rather than on oneself. In Experiment 1, we show that prosocial bonuses in the form of donations to charity lead to happier... View Details

Keywords: Satisfaction; Groups and Teams; Performance; Compensation and Benefits; Philanthropy and Charitable Giving; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Canada; Belgium; Australia

Find at Harvard

Read Now

2013
Working Paper

Prosocial Bonuses Increase Employee Satisfaction and Team Performance

By: Lalin Anik, Lara B. Aknin, Michael I. Norton, Elizabeth W. Dunn and Jordi Quoidbach

In two field studies, we explore the impact of providing employees and teammates with prosocial bonuses, a novel type of bonus spent on others rather than on oneself. In Experiment 1, we show that prosocial bonuses in the form of donations to charity lead to happier... View Details

Keywords: Satisfaction; Groups and Teams; Performance; Compensation and Benefits; Philanthropy and Charitable Giving; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Canada; Belgium; Australia

Read Now

13 Sep 2018
HBS Seminar

Ashley Swanson, Wharton, University of Pennsylvania

05 Nov 2019
News

Best Business Books 2019: Talent & leadership

May 2007 (Revised September 2008)
Case

Biocon Limited

By: Krishna G. Palepu and Ananth Chepuri

Biocon Limited was facing significant pricing pressure in their cash cow business, that primarily consisted of manufacturing Active Pharmaceutical Ingredients (APIs). To combat this commoditization, Biocon's leadership had chosen an innovation-led strategy. This new... View Details

Keywords: Globalized Firms and Management; Innovation and Management; Leading Change; Growth and Development Strategy; Risk Management; Organizational Change and Adaptation; Biotechnology Industry; India

3 Jun 2023
Talk

Health Care Innovation Opportunities Created by COVID-19 and How to Make Them Happen

By: Regina E. Herzlinger

The crush of patients created by COVID enabled the creation of sites for care outside the traditional hospital, such as retail pharmacies, ambulatory surgery centers, urgent care centers, telemedicine, and wireless sensors. Public policy mirrored these changes by... View Details

Keywords: Policy; Health Pandemics; Health Care and Treatment; Innovation and Invention; Health Industry; Insurance Industry

2006
Book

Science Business: The Promise, the Reality, and the Future of Biotech

By: Gary P. Pisano

Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of... View Details

Keywords: Science; Business Ventures; Biotechnology Industry

Find at Harvard

Branded pharmaceutical manufacturers frequently offer “copay coupons” that insulate consumers from cost-sharing, thereby undermining insurers’ ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry... View Details

04 Oct 2019
HBS Seminar

Annabelle Fowler (Harvard University), Harvard University

March 1992
Case

Amgen, Inc.: Planning the Unplannable

By: Nitin Nohria

By the early 1990s, Amgen--a pharmaceutical company started little over a decade ago as Applied Molecular Genetics--was within range of becoming a billion-dollar company. With two extremely successful biotechnology drugs on the market, Amgen stood as the largest and... View Details

Keywords: Growth and Development Strategy; Strategic Planning; Success; Risk and Uncertainty; Pharmaceutical Industry

July 2016
Case

Product Portfolio Management at Genentech

By: Kevin Schulman and Jamie Gresh

Genentech, long the darling of the biotechnology industry, was acquired by Swiss pharmaceutical company Roche in 2009. The combined company retains the name Genentech in the US, but must now move to achieve the promises made at the time of this merger—to build from... View Details

Keywords: Portfolio Management; Drug Development; Postmerger Integration; Marketing Strategy; Mergers and Acquisitions; Integration; Pharmaceutical Industry; Pharmaceutical Industry; United States

September 2007 (Revised December 2008)
Case

Michael Fernandes at Nicholas Piramal

By: Michel Anteby and Nitin Nohria

Michael Fernandes, the Director of Custom Manufacturing Operations at the pharmaceutical company Nicholas Piramal India Limited (NPIL), schedules a meeting with three of his reports, whose interpersonal conflicts with one another are causing his business development... View Details

Keywords: Interpersonal Communication; Management Skills; Groups and Teams; Conflict Management; Cooperation; Pharmaceutical Industry; India; United Kingdom; Canada